Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.
When issued, the patent will cover the use of all adeno-associated viral vectors (AAV) and routes of administration, including intracoronary, for delivery of the SERCA2a gene for the treatment of heart failure. The patent will have a term extending to at least 2023, depending on further possible time extensions due to any regulatory delays. This patent is part of Celladon's broad intellectual property portfolio for MYDICAR® and related technologies for the treatment of heart failure. Corresponding patent applications are currently pending in Europe, China, Japan and other countries.